Kei Fukami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5068767/publications.pdf

Version: 2024-02-01

59 papers	2,424 citations	26 h-index	197818 49 g-index
61	61	61	3280 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway. Diabetes, 2008, 57, 460-469.	0.6	317
2	Role of AGEs-RAGE System in Cardiovascular Disease. Current Pharmaceutical Design, 2014, 20, 2395-2402.	1.9	143
3	Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention. Current Drug Targets, 2007, 8, 952-959.	2.1	137
4	Role of AGEs in Diabetic Nephropathy. Current Pharmaceutical Design, 2008, 14, 946-952.	1.9	127
5	Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression. American Journal of Pathology, 2013, 182, 132-141.	3.8	125
6	Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs, 2008, 17, 983-996.	4.1	121
7	Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1525-1533.	6.1	106
8	Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology, 2015, 14, 2.	6.8	95
9	Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. International Journal of Cardiology, 2015, 185, 263-268.	1.7	85
10	DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy. Diabetes, 2013, 62, 3241-3250.	0.6	72
11	Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 289-295.	1.9	65
12	Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacological Research, 2010, 61, 34-39.	7.1	62
13	Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk. Rejuvenation Research, 2015, 18, 48-56.	1.8	60
14	Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvascular Research, 2008, 75, 130-134.	2.5	56
15	Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrology Dialysis Transplantation, 2013, 28, 55-62.	0.7	55
16	Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diabetes and Vascular Disease Research, 2013, 10, 436-441.	2.0	55
17	Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacological Research, 2011, 63, 241-248.	7.1	50
18	Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovascular Diabetology, 2014, 13, 60.	6.8	50

#	Article	IF	CITATIONS
19	Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism: Clinical and Experimental, 2009, 58, 1624-1628.	3.4	48
20	PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvascular Research, 2013, 85, 54-58.	2.5	48
21	Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney International, 2014, 85, 570-578.	5.2	39
22	Receptor for advanced glycation endproducts and progressive kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 54-60.	2.0	38
23	Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrology Dialysis Transplantation, 2009, 24, 1397-1406.	0.7	33
24	Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochemical and Biophysical Research Communications, 2010, 398, 326-330.	2.1	33
25	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetology and Metabolic Syndrome, 2014, 6, 86.	2.7	29
26	Potential Inhibitory Effects of <scp>I < /scp>-Carnitine Supplementation on Tissue Advanced Glycation End Products in Patients with Hemodialysis. Rejuvenation Research, 2013, 16, 460-466.</scp>	1.8	27
27	Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia. Clinical and Experimental Nephrology, 2018, 22, 35-44.	1.6	25
28	Maternal exposure to high-fat and high-fructose diet evokes hypoadiponectinemia and kidney injury in rat offspring. Clinical and Experimental Nephrology, 2016, 20, 853-861.	1.6	24
29	RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice. Scientific Reports, 2018, 8, 2686.	3 . 3	24
30	Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0203046.	2.5	23
31	Tissue level of advanced glycation end products is an independent determinant of highâ€sensitivity Câ€reactive protein levels in haemodialysis patients. Nephrology, 2011, 16, 299-303.	1.6	21
32	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clinical and Experimental Nephrology, 2018, 22, 1266-1280.	1.6	21
33	Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology, 2012, 17, 689-694.	1.6	20
34	Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4. Microvascular Research, 2018, 120, 90-93.	2.5	18
35	Uremic Toxin–Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome. Circulation Journal, 2019, 84, 2-8.	1.6	17
36	Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease. Toxins, 2021, 13, 361.	3.4	16

#	Article	IF	CITATIONS
37	L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis. Letters in Drug Design and Discovery, 2017, 14, 737-742.	0.7	14
38	Effects of Switching From Calcium Carbonate to Lanthanum Carbonate on Bone Mineral Metabolism in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2013, 17, 35-40.	0.9	13
39	Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis. Aging Male, 2014, 17, 238-242.	1.9	11
40	Effects of switching from oral administration to intravenous injection of L-carnitine on lipid metabolism in hemodialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 470-474.	2.9	11
41	Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review. BMC Nephrology, 2019, 20, 469.	1.8	11
42	Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrology Dialysis Transplantation, 2021, 37, 115-125.	0.7	11
43	<scp> </scp> â€carnitine supplementation vs cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: A randomized clinical trial. Therapeutic Apheresis and Dialysis, 2021, 25, 304-313.	0.9	10
44	Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients. Therapeutic Apheresis and Dialysis, 2014, 18, 391-397.	0.9	9
45	Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. BioResearch Open Access, 2016, 5, 155-158.	2.6	8
46	Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial. Nutrients, 2021, 13, 1900.	4.1	7
47	The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. Internal Medicine, 2017, 56, 841-846.	0.7	6
48	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6
49	Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats. Journal of Cardiology, 2021, 78, 12-16.	1.9	5
50	Carnitine deficiency is associated with decreased exercise activity in hemodialysis patients. Renal Replacement Therapy, 2019, 5 , .	0.7	4
51	Evidence for a Positive Association Between Serum Carnitine and Free Testosterone Levels in Uremic Men with Hemodialysis. Rejuvenation Research, 2013, 16, 200-205.	1.8	3
52	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. Scientific Reports, 2022, 12, .	3.3	3
53	An Overview of Diabetic Nephropathy. , 2012, , 145-157.		2
54	Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations. Clinical and Experimental Nephrology, 2021, 25, 251-260.	1.6	2

#	Article	IF	CITATIONS
55	Quantification and Visualization of Reliable Hemodynamics Evaluation Based on Non-Contact Arteriovenous Fistula Measurement. Sensors, 2022, 22, 2745.	3.8	1
56	An Overview on Diabetic Nephropathy. , 2018, , 125-137.		0
57	Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia. CEN Case Reports, 2019, 8, 205-211.	0.9	0
58	P1134HIGH PREVALENCE OF SLEEP-DISODERED BREATHING AND ITS ASSOCIATION WITH RENAL FUNCTION AMONG CHRONIC KIDNEY DISEASE PATIENTS (CKD1-5,HD AND PD) : A CROSS-SECTIONAL STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
59	Triple combination therapy with telmisartan, amlodipine, and hydrochlorothiazide ameliorates albuminuria in a normotensive rat remnant kidney model. Renal Replacement Therapy, 2021, 7, .	0.7	0